Ignite Creation Date:
2024-05-06 @ 2:41 PM
Last Modification Date:
2024-10-26 @ 1:35 PM
Study NCT ID:
NCT04390984
Status:
UNKNOWN
Last Update Posted:
2021-01-11
First Post:
2020-05-13
Brief Title:
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
A Multi-center Open-label Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous Non-small-cell Lung Cancer Patients
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients
The secondary objective of the study was to assess the pharmacokinetics of gefitinib and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients
The secondary objective of the study was to assess the pharmacokinetics of gefitinib and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None